Palbociclib in metastatic breast cancer: current evidence and real-life data

Drugs in Context

article

Francesco Serra¹  Pietro Lapidari¹  Erica Quaquarini¹  Barbara Tagliaferri¹  Federico Sottotetti¹  Raffaella Palumbo¹ 

[1] Operative Unit of Medical Oncology IRCCS-ICS Maugeri;University of Pavia

关键词: metastatic breast cancer;    palbociclib;    real-lifestudies.;   

DOI  :  10.7573/dic.212579

学科分类：社会科学、人文和艺术（综合）

来源: C S F Medical Communications Ltd.

【 摘 要 】

The purpose of this review is to summarize the backgroundand latest evidence for the use of palbociclib, an oral, first-inclass, highly selective cyclin-dependent kinase 4/6 inhibitor,in advanced breast cancer, with a focus on some of theunanswered questions about the performance of this agent inclinical practice. The available clinical data from both controlledclinical trials and real-life experiences concerning palbociclibbased combinations in patients with hormone receptor-positive(HR+)/human epidermal growth factor receptor 2-negative(HER2–) metastatic disease, including patient-reportedoutcomes and subgroup analyses, have been reviewed anddiscussed. Palbociclib significantly improved progression-freesurvival and clinical benefit rates when added to letrozole inpostmenopausal women as initial endocrine-based therapy,and it prolonged progression-free survival and overall survivalwhen added to fulvestrant in women who progressed onprevious endocrine therapy in randomized clinical trials.Tolerability profile was manageable, with neutropenia occurringmost commonly, without detrimental impact on quality oflife. Available data from real-life experiences confirm the goodperformance of palbociclib in unselected, heavily pretreatedpopulations. Palbociclib in combination with endocrine therapyis a valuable emerging option for patients with HR+/HER2–advanced or metastatic breast cancer. Further investigation isneeded to provide solutions for palbociclib resistance and toidentify the best sequence to use for the best patient benefitwith a minimal toxicity.

【 授权许可】

CC BY-NC-ND